Industry Insights: Genomic Testing for Early-Stage Breast Cancer - Top-Institutions - MDSpire

Industry Insights: Genomic Testing for Early-Stage Breast Cancer

William Audeh, Chief Medical Officer at Agendia, discusses recent data supporting genomic testing results in guiding clinical decision-making

  • March 27, 2026

  • 8 min

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    Dana-Farber Cancer Institute
    Dana-Farber Cancer Institute

    Boston, MA

    Key Differentiators

    • Breast Oncology
    • Genomic Medicine
    • Clinical Trials

  • #2

    Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer Center

    New York, NY

    Key Differentiators

    • Breast Cancer Surgery
    • Molecular Oncology
    • Genomic Profiling

  • #3

    MD Anderson Cancer Center
    MD Anderson Cancer Center

    Houston, TX

    Key Differentiators

    • Breast Cancer Research
    • Genomic Medicine
    • Clinical Trials

  • #4

    Johns Hopkins Medicine
    Johns Hopkins Medicine

    Baltimore, MD

    Key Differentiators

    • Molecular Pathology
    • Breast Cancer Genomics
    • Translational Research

  • #5

    University of California, San Francisco (UCSF) Medical Center
    University of California, San Francisco (UCSF) Medical Center

    San Francisco, CA

    Key Differentiators

    • Breast Oncology
    • Genomic Medicine
    • Clinical Research

Original Source(s)

Industry Insights: Genomic Testing for Early-Stage Breast Cancer

  • March 27, 2026

Related Content

Emerging applications of artificial intelligence for risk stratification in head and neck cancer: a scoping review

Vitamin D-related genetic variants as predictive biomarkers for breast cancer in Jordanian women

Recurrent pleuropulmonary blastoma type III initially misclassified as embryonal rhabdomyosarcoma on limited biopsy: a case report with pathogenic DICER1 variant